Everolimus API

Name	Everolimus
Chinese name	依维莫司
Cas Number	159351-69-6
Source	India
Qualifications	USDMF/-/-/-/-

Everolimus is an mTOR inhibitor developed by Novartis, Switzerland. The drug was approved by the FDA on March 30, 2009 for the treatment of patients with advanced renal cancer. Since then, the indication for everolimus has been Increasingly, including: for preventing organ rejection after kidney transplantation, for patients with subependymal giant cell astrocytoma with tuberous sclerosis, for progressive or metastatic pancreas that cannot be surgically removed Neuroendocrine tumors, used to treat hormone receptor-positive and HER2 receptor-negative postmenopausal advanced breast cancer patients, and used to prevent organ rejection after liver transplantation. Everolimus is the second-level recommended drug in the 2020 edition of the Chinese Society of Clinical Oncology Breast Cancer (CSCO BC) Diagnosis and Treatment Guidelines, and is currently the only targeted drug that can be used for ep-NET, but this indication is only approved in the United States. Compared with traditional immunosuppressive agents, the oral dose and frequency of everolimus have been reduced, with low adverse reactions, good tolerance and obvious efficacy. Novartis’ research found that everolimus can slow the growth of kidney cancer cells and reduce the mortality rate by 67%. At the same time, everolimus is also the first drug approved to treat TSC-related seizures. Everolimus has global sales of US$2.024 billion in 2019, making it one of the top 100 global pharmaceutical sales.

Hot Tags: everolimus api, China, suppliers, manufacturers, factory, customized, price, pricelist, in stock, Tavaborol API, Pleasant API, Dimethyl Fumarate API, Valganciclovir Hydrochloride API, Linagliptin API, Lapatinib Ditosylate API

• Previous: Trazodone Hydrochloride API
• Next: Lenatinib Maleate/neratinib Maleate API